CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
AssigneeSumitomo Pharma Oncology, Inc.
InventorsAdam Siddiqui-Jain, Paul Flynn, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
Life of this patent
Estimating the term…
Abstract
A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
Claims21
A pharmaceutical composition comprising crystalline Form B of a compound having the following structure (I):
- or a zwitterionic form thereof, and a pharmaceutically acceptable carrier or excipient, wherein the pharmaceutically acceptable carrier or excipient is a filler, disintegrant, lubricant or fluidizer,
- wherein crystalline Form B is characterized by an x-ray powder diffraction pattern comprising at least three peaks at 2-theta angles selected from the group consisting of 4.8±0.2°, 10.8±0.2°, 13.7±0.2°, 14.9±0.2°, 20.0±0.2° and 24.6±0.2°.
A pharmaceutical composition comprising:
- crystalline Form B of a compound having the following structure (I):
- or a zwitterionic form thereof;
- (ii) a pharmaceutically acceptable carrier or excipient;
- (iii) a glidant;
- and
- (iv) a lubricant;
- wherein crystalline Form B is characterized by an x-ray powder diffraction pattern comprising at least three peaks at 2-theta angles selected from the group consisting of 4.8±0.2°, 10.8±0.2°, 13.7±0.2°, 14.9±0.2°, 20.0±0.2° and 24.6±0.2°.
A method for treating a cancer in a mammal in need thereof, comprising administering to the mammal crystalline Form B of a compound having the following structure (I):
- or a zwitterionic form thereof, in an amount of from about 1 mg to about 30 mg per day,
- wherein crystalline Form B is characterized by an x-ray powder diffraction pattern comprising at least three peaks at 2-theta angles selected from the group consisting of 4.8±0.2°, 10.8±0.2°, 13.7±0.2°, 14.9±0.2°, 20.0±0.2° and 24.6±0.2°.
Dependencies are inferred from the claim text.